BioGaia AB (publ) (BIOG_B) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hi, this is Theresa Agnew, CEO of BIOGaia, and I am here with Alexander Kotzinas, and we are here to present our Q2 results for 2026. So some of the highlights of the quarter: our growth, excluding currency effects, was 12% versus a year ago, and our EBIT margin is 30%, with an adjusted EBIT margin of 33% for the quarter. Overall, our net sales reached SEK441 million, as I said, with growth excluding currency effects of 12%. Specifically in the regions, in Europe, Middle East, Africa, our sales increased by 21, excluding currency effects. In The Americas increased by 16% excluding currency effects, while Asia Pacific decreased by 6% excluding currency effects due to order variability. Our operating profit in the quarter was SEK132 million, which is an increase of 22%, and our EBIT margin was 30% versus the 27% last year for Q2. Our adjusted EBIT margin was 33% for the quarter. Overall, our net sales year to date reached SEK $813,000,000, which is growth excluding currency effects of 13%. Our BIOGaia company strategy remains the same. Our first strategic pillar is grow the core, the core being our core health areas of the business, of which gut health, which includes colic, oral health, and immune health are our biggest priorities. Our second strategic pillar is what we call expansion through direct markets, where we look at particular markets to take from a distributor partnership to a subsidiary or a direct market. We currently have 12 direct markets. And our third strategic pillar is breakthrough innovation. This is market creation opportunities for probiotics where people don't routinely use probiotics today. The foundations of our company are people and culture, investing for profitable growth, using digital as an enabler both in how we go to market through our o...